Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (771)	10/14/1998 5:48:00 PM
From: Hong-Lee Yu	Read Replies (1) \| Respond to of 1686

All, Today's PFE price action bodes well for all drug/biotech stocks. PFE missed Q3 EPS by more 0.5C (10%). Yet the stock more than recover yesterday's loss. CNBC is very naiive in predicting weak opening for PFE. On the other hands, INTC beats the most bullish estimates by a couple of cents and yet the stock retreats 1 (i owned both). My interpretation is most people thinks the stock is undervalued, but worry about next year's corporate earnings. They will pay the premium for consistent earnings. BGEN fits the profile.